| Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients J Sabbatinelli, A Giuliani, G Matacchione, S Latini, N Laprovitera, ... Mechanisms of ageing and development 193, 111413, 2021 | 107 | 2021 |
| Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications E Porcellini, N Laprovitera, M Riefolo, M Ravaioli, I Garajova, M Ferracin Cancer letters 419, 84-95, 2018 | 63 | 2018 |
| Cancer of unknown primary: challenges and progress in clinical management N Laprovitera, M Riefolo, E Ambrosini, C Klec, M Pichler, M Ferracin Cancers 13 (3), 451, 2021 | 58 | 2021 |
| DNA methylation of shelf, shore and open sea CpG positions distinguish high microsatellite instability from low or stable microsatellite status colon cancer stem cells R Visone, MG Bacalini, SD Franco, M Ferracin, ML Colorito, S Pagotto, ... Epigenomics 11 (6), 587-604, 2019 | 47 | 2019 |
| KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC M Cinausero, N Laprovitera, GD Maglio, L Gerratana, M Riefolo, ... Therapeutic Advances in Medical Oncology 11, 1758835919885540, 2019 | 36 | 2019 |
| MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary N Laprovitera, M Riefolo, E Porcellini, G Durante, I Garajova, F Vasuri, ... Molecular Oncology 15 (10), 2732-2751, 2021 | 29 | 2021 |
| Cancer site-specific multiple microRNA quantification by droplet digital PCR N Laprovitera, M Grzes, E Porcellini, M Ferracin Frontiers in oncology 8, 447, 2018 | 22 | 2018 |
| Genetic characterization of cancer of unknown primary using liquid biopsy approaches N Laprovitera, I Salamon, F Gelsomino, E Porcellini, M Riefolo, M Garonzi, ... Frontiers in Cell and Developmental Biology 9, 666156, 2021 | 17 | 2021 |
| Circulating miR-184 is a potential predictive biomarker of cardiac damage in Anderson–Fabry disease I Salamon, E Biagini, P Kunderfranco, R Roncarati, M Ferracin, N Taglieri, ... Cell Death & Disease 12 (12), 1150, 2021 | 13 | 2021 |
| The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer M Mazzeschi, M Sgarzi, D Romaniello, V Gelfo, C Cavallo, F Ambrosi, ... Journal of Experimental & Clinical Cancer Research 41 (1), 113, 2022 | 9 | 2022 |
| Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity S De Matteis, M Dicataldo, B Casadei, G Storci, N Laprovitera, M Arpinati, ... Frontiers in Immunology 13, 1058126, 2023 | 8 | 2023 |
| Pre-transplant CD69+ extracellular vesicles are negatively correlated with active ATLG serum levels and associate with the onset of GVHD in allogeneic HSCT patients G Storci, F Barbato, F Ricci, PL Tazzari, S De Matteis, E Tomassini, ... Frontiers in Immunology 13, 1058739, 2023 | 4 | 2023 |
| CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells G Storci, F De Felice, F Ricci, S Santi, D Messelodi, SN Bertuccio, ... The Journal of Clinical Investigation 134 (14), 2024 | 3 | 2024 |
| A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after … G Chirumbolo, M Dicataldo, M Barone, G Storci, S De Matteis, ... Transplantation and Cellular Therapy 29 (5), 302. e1-302. e8, 2023 | 3 | 2023 |
| MicroRNA and metabolic profiling of a primary ovarian neuroendocrine carcinoma pulmonary-type reveals a high degree of similarity with small cell lung cancer S Miglietta, G Girolimetti, L Marchio, M Sollazzo, N Laprovitera, ... Non-coding RNA 8 (5), 64, 2022 | 3 | 2022 |
| Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy S De Matteis, B Casadei, G Lolli, M Dicataldo, F Barbato, E Dan, ... Frontiers in Immunology 13, 994731, 2022 | 2 | 2022 |
| Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary A Cavazzoni, I Salamon, C Fumarola, G Gallerani, N Laprovitera, ... Molecular Therapy 32 (10), 3650-3668, 2024 | 1 | 2024 |
| A Multiparameter Prognostic Risk Score of Chronic GVHD based on CXCL10 and Plasmacytoid DC (pDC) levels in the Peripheral Blood at 3 months after Allogeneic Hematopoietic Stem … G Chirumbolo, M Dicataldo, M Barone, G Storci, S De Matteis, ... Transplantation and Cellular Therapy, S2666-6367 (23) 01101, 2023 | 1 | 2023 |
| Sickle Cell Trait and SARS-CoV-2-Induced Rhabdomyolysis: A Case Report G Donati, C Abenavoli, G Vischini, G Cenacchi, R Costa, G Pasquinelli, ... The American Journal of Case Reports 23, e934220-1, 2022 | 1 | 2022 |
| MicroRNA and Metabolic Profiling of a Primary Ovarian Neuroendocrine Carcinoma Pulmonary-Type Reveals a High Degree of Similarity with Small Cell Lung Cancer. Non-Coding RNA … S Miglietta, G Girolimetti, L Marchio, M Sollazzo, N Laprovitera, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2022 | 1 | 2022 |